After Lilly's GLP-1 sales fumble, Novo reports mixed results on Ozempic, Wegovy
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its GLP-1 stalwarts Ozempic and Wegovy is more of a mixed bag. | Among Novo’s semaglutide-based drugs,
Wegovy sales are slaying for Novo Nordisk right now
Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The Danish pharma giant posted its third-quarter earnings report early Tuesday morning and boasted sales figures blowing past analysts’ projections.
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Ozempic sales were a bit lower than expected in the quarter at DKK 29.8 billion, while Wegovy sales were higher at DKK 17.3 ...
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...
Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.
4don MSN
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback